Uveal Melanoma Treatment Market By Treatment Type (Radiation Therapy, Surgical Treatment, Systemic Drug Therapy, Liver-Directed Therapy); By Application (Localized Uveal Melanoma, Unresectable or Metastatic Uveal Melanoma); By End User (Hospitals and Cancer Centers, Ocular Oncology Centers, Radiation Oncology Centers, Specialty Clinics and Infusion Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Uveal Melanoma Treatment Market — Specialized Local Care and Recurring Metastatic Therapy Reshape Commercial Value

The Global Uveal Melanoma Treatment Market was valued at USD 0.95 billion in 2025 and is projected to reach USD 2.10 billion by 2032, expanding at a CAGR of 12.0% during 2026–2032, according to Strategic Market Research.

 

The treatment landscape for metastatic or unresectable uveal melanoma remains limited. Tebentafusp-tebn (Kimmtrak) is currently the only FDA-approved systemic therapy, while percutaneous hepatic perfusion with melphalan represents the only FDA-approved liver-directed treatment. Nevertheless, the development pipeline is expanding, with investigational approaches such as darovasertib, belzupacap sarotalocan, and tumor-infiltrating lymphocyte therapies offering potential new treatment options for patients with advanced disease.

 

Rare Incidence Concentrates Demand in Specialist Networks

In the United States and globally, mortality from uveal melanoma is mainly associated with metastatic disease, particularly when it spreads to the liver. While localized tumors have a 5-year survival rate of about 75%–84%, survival falls to approximately 15% after metastasis. Overall, an estimated 30%–44% of patients die from the disease within 20 years of initial treatment.

Most patients initially enter the localized pathway. A SEER analysis of 7,516 patients diagnosed between 1989 and 2019 found that 90.9% had localized disease at presentation, while 1.6% had distant metastases. Localized cases therefore represented more than nine out of every ten newly diagnosed patients in this cohort, giving eye-directed procedures the largest initial patient share. Pharmaceutical demand develops later as some patients progress to metastatic disease.

Around half of patients may eventually develop metastases, although progression timing varies. Biomarker status, organ involvement, performance status, treatment suitability and specialist access further narrow the advanced-treatment pool. Patient identification and referral conversion are consequently more important than broad population growth.

Demand is institutionally concentrated. UK manages approximately 600 new cases annually through four principal supra-specialist ocular oncology centers, equivalent to an average referral pool of about 150 new cases per center before differences in case distribution. France records around 500 new cases each year, with Institut Curie treating a substantial share. This concentration favors targeted engagement with referral centers, radiation departments, oncology networks and payers.

 

Eye-Preserving Radiation Leads Localized Treatment

Surgical trends: Enucleation was the dominant treatment for uveal melanoma in the late 1970s, performed in up to 93% of patients. By 2020, primary surgery rates had declined to about 21% as globe-preserving approaches became preferred. Secondary enucleation is now mainly reserved for tumor recurrence, uncontrolled disease, or severe radiation-related complications.

Radiation trends: Radiation therapy is currently the standard first-line treatment for most localized uveal melanomas. Plaque brachytherapy is the most widely used modality, followed by proton beam radiotherapy and stereotactic radiosurgery. These approaches provide high rates of local tumor control while preserving the eye, although radiation retinopathy and neovascular glaucoma may later require surgical intervention.

This change has redirected treatment value toward ocular oncology centers, plaque-brachytherapy programs, radiation departments and specialized external-beam or proton facilities. Plaque brachytherapy and external-beam radiation are preferred eye-sparing options for many medium-sized choroidal melanomas. Enucleation remains necessary for large tumors, severe secondary glaucoma, optic-nerve involvement and other locally complex cases.

Radiation is the dominant localized segment, with a 58% treatment share in the 2017–2020 SEER period, while surgery-only approaches retained 21%. These are treatment-mix shares rather than revenue shares because procedure costs and reimbursement differ across radiation, proton therapy, plaque placement and surgery.

Plaque treatment creates demand for radiation planning, operating-room procedures and specialist follow-up. Proton therapy remains concentrated in capital-intensive referral facilities. Localized care generates mainly episodic revenue, unlike the weekly or repeat-cycle revenue generated by advanced therapies.

 

KIMMTRAK Establishes a High-Value Recurring Drug Segment

KIMMTRAK, or tebentafusp-tebn, is FDA approved for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma. Approximately half of the uveal melanoma population carries this tissue type, placing the biomarker-positive subsegment at roughly 50% of patients before other eligibility exclusions.

KIMMTRAK is a bispecific soluble T-cell receptor therapy that recognizes a gp100-derived peptide presented by HLA-A*02:01 and recruits T cells through CD3 binding. Its commercial demand is directly linked to HLA testing, metastatic diagnosis and access to qualified infusion settings.

Treatment is administered weekly and continues until progression or unacceptable toxicity. The first three infusions require extended monitoring, concentrating initiation in experienced facilities, while later infusions can move to outpatient or community settings when appropriate.

Immunocore reported KIMMTRAK net product sales of USD 400.0 million in 2025, an increase of 29% over 2024. Against the USD 0.95 billion global market value, KIMMTRAK represented approximately 42.1% of total 2025 market revenue. U.S. sales reached USD 257.0 million, equivalent to 27.1% of the global market and 64.3% of KIMMTRAK revenue. European sales reached USD 131.4 million, representing 13.8% of the global market and 32.9% of product sales, while other international markets contributed USD 11.6 million, or 2.9% of KIMMTRAK revenue.

The company had approvals in 39 countries and launches in 30 countries by the end of 2025. European revenue increased 79% in 2025, compared with 13% growth in the United States. Europe expanded faster from a smaller base, while the United States remained the largest disclosed market.

KIMMTRAK generated USD 106.7 million in the first quarter of 2026, up 13.6% year over year. A reported mean U.S. treatment duration of 14 months gives each initiated patient a high number of recurring treatment events and supports substantial revenue from a narrow population.

 

HEPZATO Expands the Procedure-Linked Metastatic Segment

HEPZATO KIT combines melphalan with a hepatic delivery system for adults with eligible unresectable liver metastases. The FDA indication applies when hepatic disease affects less than half of the liver and extrahepatic disease is absent or limited enough to be managed through surgery or radiation.

During percutaneous hepatic perfusion, melphalan is infused through the hepatic artery while blood leaving the liver is temporarily isolated, filtered outside the body and returned to circulation. Treatment is administered every six to eight weeks for up to six infusions.

This model creates drug, device and hospital procedure revenue. Delcath supplies the treatment system, while hospitals generate revenue from interventional services, anesthesia, monitoring, staffing and facility use. Adoption depends on referrals, trained teams, infrastructure and reimbursement.

Delcath reported USD 78.8 million in U.S. HEPZATO revenue during 2025, equivalent to approximately 8.3% of the global market. Combined KIMMTRAK and HEPZATO revenue reached USD 478.8 million, representing about 50.4% of the 2025 global market estimate.

HEPZATO procedure volume increased approximately 140% compared with 2024, while the active network reached 28 centers by February 2026. First-quarter 2026 revenue reached USD 23.3 million. Although eligibility depends on liver tumor burden, extrahepatic disease and procedural suitability, repeat treatment and center expansion support a high-value advanced-disease segment.

 

Pricing and Reimbursement Shape Realized Demand

Premium pricing is supported by disease rarity, limited approved alternatives and high clinical specialization. Payer negotiations, treatment duration and site-of-care economics determine realized revenue.

NICE lists KIMMTRAK at GBP 10,114 for a 200-microgram vial and recommends treatment under a confidential commercial arrangement. Canadian reimbursement analysis estimated that tebentafusp could create a three-year public-payer budget impact of approximately CAD 54.0 million. Weekly dosing and prolonged treatment increase both manufacturer revenue and payer exposure.

HEPZATO reimbursement is more institution dependent because hospitals must cover the product alongside interventional staffing, anesthesia, filtration, monitoring and operating time. Companies combining regulatory approval with payer access, coding support, referral development and workable hospital economics are positioned to capture the largest share of the market’s 12.0% CAGR.

 

Uveal Melanoma Treatment Market Segmentation

By Treatment Pathway

Eye-directed radiation is the leading localized segment, supported by its 58% share of recorded SEER cases during 2017–2020. Enucleation remains important for large or locally complex tumors but represented a smaller 21% contemporary treatment share.

The metastatic pharmaceutical segment provides the strongest recurring revenue. KIMMTRAK generated USD 400.0 million and represented approximately 42.1% of the 2025 global market, while HEPZATO generated USD 78.8 million and represented about 8.3%. Together, the two approved therapies accounted for approximately 50.4% of the global market value.

 

By Disease Stage

Localized disease accounts for most initial treatment activity because 90.9% of patients in the cited SEER cohort presented with localized disease. Revenue is concentrated in ocular oncology, radiation services and specialist procedures.

Metastatic disease represents a smaller but higher-value recurring segment. Weekly KIMMTRAK administration and repeat HEPZATO procedures produce more billable events per patient. Their combined USD 478.8 million revenue demonstrates the commercial weight of advanced disease despite its smaller treated population.

 

By Biomarker Status

HLA-A02:01-positive metastatic disease forms the established KIMMTRAK segment and represents approximately 50% of the broader population before clinical and access exclusions. HLA-A02:01-negative patients form the other major biomarker subsegment and remain an important development category for therapies such as darovasertib.

 

By End User

Specialized ocular oncology and radiation centers dominate localized care. Hospital outpatient departments, cancer centers and selected community infusion providers administer KIMMTRAK. HEPZATO remains concentrated in qualified hospitals with interventional oncology and multidisciplinary capacity.

 

Regional Market Dynamics

North America has the strongest publicly visible advanced-treatment revenue. U.S. KIMMTRAK sales reached USD 257.0 million in 2025, equivalent to 27.1% of the global market, while HEPZATO generated USD 78.8 million, equal to approximately 8.3%. Together, these disclosed U.S. revenues represented USD 335.8 million, or roughly 35.3% of the global market value.

Europe is expanding through country-level reimbursement and centralized specialist networks. KIMMTRAK generated USD 131.4 million in European revenue in 2025, representing approximately 13.8% of the global market and 32.9% of product sales. Its 79% European growth rate exceeded the 13% U.S. increase, showing stronger recent expansion from reimbursement and new launches.

England’s approximately 600 annual cases are managed through a small number of supra-specialist centers. France has around 500 annual diagnoses, with leading academic institutions controlling a substantial referral share. Canada offers a smaller payer-controlled market in which reimbursement conditions and budget impact influence uptake.

 

Pipeline Competition Targets Biomarker Gaps and Earlier Disease

Darovasertib Plus Crizotinib

IDEAYA Biosciences and Servier are developing darovasertib with crizotinib for first-line HLA-A*02:01-negative metastatic disease. Darovasertib inhibits protein kinase C signaling associated with GNAQ and GNA11 mutations, while crizotinib targets c-MET signaling.

The OptimUM-02 Phase 2/3 trial met its primary progression-free-survival endpoint. Company-reported median progression-free survival was 6.9 months with the combination versus 3.1 months for investigator-selected therapy, with a hazard ratio of 0.42.

The companies initiated the NDA process through the FDA’s Real-Time Oncology Review program in 2026. Approval could establish a recurring oral treatment for the approximately 50% HLA-A*02:01-negative subsegment and change first-line sequencing.

 

Belzupacap Sarotalocan

Aura Biosciences is evaluating belzupacap sarotalocan, or bel-sar, in the Phase 3 CoMpass trial for early choroidal melanoma. Enrollment of 108 patients was completed in June 2026, with topline results expected in the second half of 2027.

Bel-sar binds modified heparan sulfate proteoglycans on ocular tumor cells and uses infrared-light activation to produce localized tumor-cell death. Positive results could move pharmaceutical revenue into localized disease, where radiation currently holds a 58% treatment share.

 

Lifileucel

Lifileucel, or LN-144, is being studied in a Phase 1 trial that includes metastatic uveal melanoma. This autologous tumor-infiltrating lymphocyte therapy requires tumor collection, centralized cell expansion, lymphodepleting treatment and specialized center support. Its operational complexity is likely to restrict use to advanced cellular-therapy centers.

 

Competitive Landscape

Immunocore is the commercial pharmaceutical leader through KIMMTRAK, which generated USD 400.0 million and captured approximately 42.1% of the 2025 global market. Delcath is the principal procedure-linked metastatic-treatment company through HEPZATO, with USD 78.8 million in revenue and an estimated 8.3% global market share.

IDEAYA and Servier are the most advanced challengers in HLA-A*02:01-negative metastatic disease. Aura Biosciences is developing a potential earlier-stage alternative to localized radiation, while lifileucel introduces a longer-term personalized cell-therapy opportunity.

Competition will occur mainly within each disease stage. Radiation, enucleation and bel-sar may compete for selected localized patients. KIMMTRAK, HEPZATO, darovasertib-based therapy and future cell treatments may compete or be used sequentially according to HLA status, liver involvement, previous therapy and clinical suitability.

 

Strategic Outlook

The market is projected to expand from USD 0.95 billion in 2025 to USD 2.10 billion by 2032 at a CAGR of 12.0%, adding approximately USD 1.15 billion in revenue and expanding by about 121%.

Localized care will continue to generate the largest initial patient flow, with radiation holding a 58% treatment share. Metastatic treatment will produce the strongest recurring revenue because weekly infusions and repeat liver-directed procedures create more treatment events per patient.

KIMMTRAK held an estimated 42.1% share of the 2025 global market, while HEPZATO contributed approximately 8.3%. Their combined 50.4% share shows that advanced therapies already control a substantial portion of market revenue despite serving a narrower population than localized treatment.

Darovasertib could open the approximately 50% HLA-A*02:01-negative metastatic subsegment, while bel-sar could bring pharmaceutical competition into early choroidal melanoma. Suppliers with the strongest position will combine clinical differentiation with biomarker testing, reimbursement access, specialist referral networks and efficient site-of-care delivery.

 

Uveal Melanoma Treatment Market Report Coverage Table

 

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 0.95 Billion
Revenue Forecast in 2032	USD 2.10 Billion
Overall Growth Rate	CAGR of 12.0% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Application, By End User, By Geography
By Treatment Type	Radiation Therapy, Surgical Treatment, Systemic Drug Therapy, Liver-Directed Therapy
By Application	Localized Uveal Melanoma, Unresectable or Metastatic Uveal Melanoma
By End User	Hospitals and Cancer Centers, Ocular Oncology Centers, Radiation Oncology Centers, Specialty Clinics and Infusion Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	• Rising adoption of advanced ocular oncology therapies and precision treatment approaches • Increasing demand for targeted therapies and liver-directed interventions for metastatic disease • Growing focus on early diagnosis and specialized melanoma treatment infrastructure
Customization Option	Available upon request